Shui-On Leung Selected Research

Non-Hodgkin Lymphoma (Lymphosarcoma)

11/2021

An open-label, multiple-dose study to assess the preliminary pharmacokinetics, pharmacodynamics, clinical activity, and safety of human mouse chimeric anti-CD22 monoclonal antibody (SM03) in patients with rheumatoid arthritis.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Shui-On Leung Research Topics

Disease

2	Rheumatoid Arthritis 01/2022 - 11/2021
2	Systemic Lupus Erythematosus (Libman-Sacks Disease) 11/2021 - 11/2016
2	Lymphoma (Lymphomas) 01/2015 - 01/2014
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 11/2021
1	Autoimmune Diseases (Autoimmune Disease) 01/2015

Drug/Important Bio-Agent (IBA)

4	Monoclonal AntibodiesIBA 01/2022 - 01/2014
1	AntibodiesIBA 11/2021
1	Sialic Acid Binding Ig-like Lectin 2IBA 01/2015